HLB Life Science Co., Ltd. (KOSDAQ:067630)
2,290.00
-60.00 (-2.55%)
Nov 18, 2026, 3:30 PM KST
HLB Life Science Revenue
HLB Life Science had revenue of 15.19B KRW in the quarter ending September 30, 2026, with 11.76% growth. This brings the company's total for the last twelve months to 55.99B, up 24.82% year-over-year. In the year 2025, HLB Life Science had annual revenue of 45.75B with 39.61% growth. That makes HLB Life Science the 29,222nd largest company in the world by revenue and 1,800th in South Korea.
Revenue (ttm)
55.99B
Revenue Growth
+24.82%
P/S Ratio
4.98
Revenue / Employee
363.56M
Employees
154
Market Cap
279.03B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full HLB Life Science breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.75B | 12.98B | 39.61% |
| Dec 31, 2024 | 32.77B | -65.22B | -66.56% |
| Dec 31, 2023 | 97.99B | -1.60B | -1.61% |
| Dec 31, 2022 | 99.59B | 46.10B | 86.17% |
| Dec 31, 2021 | 53.49B | -38.30B | -41.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| ALTEOGEN | 254.01B |
| WON TECH | 167.35B |
| Curexo | 77.74B |
| MEDIPOST | 74.84B |
| SillaJen | 10.77B |